Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02658890 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 627
- Enrollment target
NCT02658890 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 627 participants.
The verdict
NCT02658890, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 627 participants
- Enrollment target
Study Summary
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2016-04-14 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02658890
The ClinicalTrials.gov registry entry for NCT02658890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 627 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02658890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02658890 about?
NCT02658890 is a clinical study titled "An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread". The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 wh...
What is the current status of trial NCT02658890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 627 participants. The study started on 2016-04-14. Estimated completion is 2021-10-26.
What interventions are being tested in trial NCT02658890?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT02658890?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.